Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
PFIZER | ORCHID PHARMA LTD | PFIZER/ ORCHID PHARMA LTD |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.4 | -0.1 | - | View Chart |
P/BV | x | 5.0 | 0.1 | 6,923.6% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-18 |
ORCHID PHARMA LTD Sep-13 |
PFIZER/ ORCHID PHARMA LTD |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,365 | 194 | 1,219.1% | |
Low | Rs | 1,625 | 35 | 4,642.9% | |
Sales per share (Unadj.) | Rs | 430.3 | 276.5 | 155.6% | |
Earnings per share (Unadj.) | Rs | 78.7 | -79.2 | -99.4% | |
Cash flow per share (Unadj.) | Rs | 93.2 | -43.5 | -214.5% | |
Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 586.5 | 53.9 | 1,087.4% | |
Shares outstanding (eoy) | m | 45.75 | 70.45 | 64.9% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 4.6 | 0.4 | 1,119.5% | |
Avg P/E ratio | x | 25.3 | -1.4 | -1,753.5% | |
P/CF ratio (eoy) | x | 21.4 | -2.6 | -812.4% | |
Price / Book Value ratio | x | 3.4 | 2.1 | 160.2% | |
Dividend payout | % | 25.4 | 0 | - | |
Avg Mkt Cap | Rs m | 91,271 | 8,067 | 1,131.5% | |
No. of employees | `000 | 2.6 | 2.8 | 93.9% | |
Total wages/salary | Rs m | 3,143 | 2,527 | 124.4% | |
Avg. sales/employee | Rs Th | 7,484.8 | 6,956.1 | 107.6% | |
Avg. wages/employee | Rs Th | 1,195.0 | 902.5 | 132.4% | |
Avg. net profit/employee | Rs Th | 1,369.1 | -1,993.0 | -68.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 19,685 | 19,477 | 101.1% | |
Other income | Rs m | 1,143 | 407 | 280.7% | |
Total revenues | Rs m | 20,828 | 19,884 | 104.7% | |
Gross profit | Rs m | 5,003 | 1,103 | 453.7% | |
Depreciation | Rs m | 663 | 2,519 | 26.3% | |
Interest | Rs m | 4 | 5,227 | 0.1% | |
Profit before tax | Rs m | 5,479 | -6,236 | -87.9% | |
Minority Interest | Rs m | 0 | 20 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 511 | 0.0% | |
Tax | Rs m | 1,878 | -125 | -1,500.3% | |
Profit after tax | Rs m | 3,601 | -5,580 | -64.5% | |
Gross profit margin | % | 25.4 | 5.7 | 448.9% | |
Effective tax rate | % | 34.3 | 2.0 | 1,707.6% | |
Net profit margin | % | 18.3 | -28.7 | -63.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,167 | 11,014 | 219.4% | |
Current liabilities | Rs m | 9,544 | 32,060 | 29.8% | |
Net working cap to sales | % | 74.3 | -108.1 | -68.7% | |
Current ratio | x | 2.5 | 0.3 | 737.0% | |
Inventory Days | Days | 55 | 95 | 58.1% | |
Debtors Days | Days | 29 | 34 | 85.5% | |
Net fixed assets | Rs m | 9,514 | 29,440 | 32.3% | |
Share capital | Rs m | 458 | 705 | 64.9% | |
"Free" reserves | Rs m | 26,375 | 2,043 | 1,291.2% | |
Net worth | Rs m | 26,832 | 3,800 | 706.1% | |
Long term debt | Rs m | 25 | 9,018 | 0.3% | |
Total assets | Rs m | 36,900 | 46,510 | 79.3% | |
Interest coverage | x | 1,305.5 | -0.2 | -676,029.0% | |
Debt to equity ratio | x | 0 | 2.4 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.4 | 127.4% | |
Return on assets | % | 9.8 | -0.8 | -1,285.4% | |
Return on equity | % | 13.4 | -146.9 | -9.1% | |
Return on capital | % | 20.4 | -3.7 | -546.7% | |
Exports to sales | % | 0 | 37.9 | 0.0% | |
Imports to sales | % | 0 | 22.6 | 0.0% | |
Exports (fob) | Rs m | NA | 7,378 | 0.0% | |
Imports (cif) | Rs m | NA | 4,406 | 0.0% | |
Fx inflow | Rs m | 22 | 7,513 | 0.3% | |
Fx outflow | Rs m | 1,489 | 5,649 | 26.4% | |
Net fx | Rs m | -1,466 | 1,865 | -78.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,318 | 1,682 | 197.3% | |
From Investments | Rs m | -2,383 | -9,860 | 24.2% | |
From Financial Activity | Rs m | -1,104 | 6,644 | -16.6% | |
Net Cashflow | Rs m | -169 | -1,535 | 11.0% |
Indian Promoters | % | 0.0 | 32.3 | - | |
Foreign collaborators | % | 63.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.5 | 4.6 | 163.0% | |
FIIs | % | 4.9 | 3.3 | 148.5% | |
ADR/GDR | % | 0.0 | 4.6 | - | |
Free float | % | 23.7 | 55.3 | 42.9% | |
Shareholders | 85,207 | 84,811 | 100.5% | ||
Pledged promoter(s) holding | % | 0.0 | 54.9 | - |
Compare PFIZER With: IPCA LABS NOVARTIS DR. DATSONS LABS MERCK LTD GSK PHARMA
Compare PFIZER With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.
Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.
For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
More Views on NewsTanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
The real estate sector is ready to make a comeback. This is the stock to consider buying.
While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More
| |